AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.